Pfizer: Plans For Boosters Will Not Divert Supplies From Poorer Nations
Manufacturing Output Could End Vaccine Inequity In 2022
Executive Summary
Pfizer has pledged to supply 41% of its COVID-19 vaccine output to developing nations – but warns that these countries still need to sign contracts on time to guarantee supplies.
You may also be interested in...
Yes We Can: South African Scientists On Their Way With mRNA Vaccine
South African researchers make own version of mRNA COVID-19 vaccine that uses “recipes” available in the public domain but one that is eventually expected to be “second generation” and can be more applicable to use in low- and middle-income countries. The initiative, under the wider WHO-backed mRNA vaccine technology hub, doesn’t see Moderna or BioNTech intellectual property as being a barrier.
US FDA Signals New COVID-19 Vaccines Could Be Authorized With Just Immunogenicity Studies
As FDA lowers some expectations on timing of booster shots, agency’s outgoing vaccine chief says second-generation COVID vaccines may be authorized without efficacy studies. Marion Gruber's conclusion was supported by many of her international regulatory peers during a WHO meeting.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.